Human RAGE Antibody

  • Specificity
    Detects human RAGE in ELISAs and Western blots. In Western blots, this antibody shows approximately 25% cross-reactivity with recombinant mouse RAGE and recombinant rat RAGE.
  • Source
    Monoclonal Mouse IgG2B Clone # 176902
  • Purification
    Protein A or G purified from hybridoma culture supernatant
  • Immunogen
    Mouse myeloma cell line NS0-derived recombinant human RAGE
    Accession # Q15109
  • Formulation
    Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
  • Endotoxin Level
    <0.01 EU per 1 μg of the antibody by the LAL method.
  • Label
  • Western Blot
    2 µg/mL
    See below
  • Blockade of Receptor-ligand Interaction
    In a functional ELISA, 1 - 3 μg/mL of this antibody will block 50% of the binding of 500 ng/mL of biotinylated AGE-BSA to immobilized recombinant human RAGE/Fc Chimera coated at 5 μg/mL (100 µL/well). At 10 μg/mL, this antibody will block >90% of the binding.
    • Human RAGE Sandwich Immunoassay
  • ELISA Capture
    2-8 µg/mL 
    Human RAGE Antibody (Catalog # MAB11451)
  • ELISA Detection
    0.1-0.4 µg/mL 
    Human RAGE Biotinylated Antibody (Catalog # BAF1145)
  • ELISA Standard
    Recombinant Human RAGE Fc Chimera Protein, CF (Catalog # 1145-RG)
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Data Examples
Detection of Human RAGE by Western Blot. Western blot shows lysates of human lung tissue. PVDF Membrane was probed with 2 µg/mL of Mouse Anti-Human RAGE Monoclonal Antibody (Catalog # MAB11451) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Specific bands were detected for RAGE at approximately 43 kDa under non-reducing (NR) conditions and 50 kDa under reducing (R) conditions (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Preparation and Storage
  • Reconstitution
    Reconstitute at 0.5 mg/mL in sterile PBS.
  • Shipping
    The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
  • Stability & Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 12 months from date of receipt, -20 to -70 °C as supplied.
    • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
    • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: RAGE

Advanced glycation endproducts (AGE) are adducts formed by the non-enzymatic glycation or oxidation of macromolecules (1). AGE forms during aging and its formation is accelerated under pathophysiologic states such as diabetes, Alzheimer’s disease, renal failure and immune/inflammatory disorders. Receptor for Advanced Glycation Endoproducts (RAGE), named for its ability to bind AGE, is a multi-ligand receptor belonging the immunoglobulin (Ig) superfamily. Besides AGE, RAGE binds amyloid beta -peptide, S100/calgranulin family proteins, high mobility group B1 (HMGB1, also know as amphoterin) and leukocyte integrins (1, 2).

The human RAGE gene encodes a 404 amino acid residues (aa) type I transmembrane glycoprotein with a 22 aa signal peptide, a 320 aa extracellular domain containing an Ig-like V-type domain and two Ig-like Ce-type domains, a 21 aa transmembrane domain and a 41 aa cytoplasmic domain (3). The V-type domain and the cytoplasmic domain are important for ligand binding and for intracellular signaling, respectively. Two alternative splice variants, lacking the V-type domain or the cytoplasmic tail, are known (1, 4). RAGE is highly expressed in the embryonic central nervous system (5). In adult tissues, RAGE is expressed at low levels in multiple tissues including endothelial and smooth muscle cells, mononuclear phagocytes, pericytes, microglia, neurons, cardiac myocytes and hepatocytes (6). The expression of RAGE is upregulated upon ligand interaction. Depending on the cellular context and interacting ligand, RAGE activation can trigger differential signaling pathways that affect divergent pathways of gene expression (1, 7). RAGE activation modulates varied essential cellular responses (including inflammation, immunity, proliferation, cellular adhesion and migration) that contribute to cellular dysfunction associated with chronic diseases such as diabetes, cancer, amyloidoses and immune or inflammatory disorders (1).

  • References:
    1. Schmidt, A. et al. (2001) J. Clin. Invest. 108:949.
    2. Chavakis, T. et al. (2003) J. Exp. Med. 198:507.
    3. Neeper, M. et al. (1992) J. Biol. Chem. 267:14998.
    4. Yonekura, H. et al. (2003) Biochem. J. 370:1097.
    5. Hori, O. et al. (1995) J. Biol. Chem. 270:25752.
    6. Brett, J. et al. (1993) Am. J. Pathol. 143:1699.
    7. Valencia, J.V. et al. (2004) Diabetes 53:743.
  • Long Name:
    Receptor for Advanced Glycation End Products
  • Entrez Gene IDs:
    177(Human); 11596(Mouse); 81722(Rat)
  • Alternate Names:
    AGER; EC; MOK protein kinase; MOKMAPK/MAK/MRK overlapping kinase; RAGE-1; RAGE1renal cell carcinoma antigen (MOK protein kinase); renal tumor antigen; Renal tumor antigen 1
Related Research Areas

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

Showing Results 1 - 5 of 5
Filter your results:

Sample Type
  1. Soluble receptor for advanced glycation end products as an indicator of pulmonary vascular injury after cardiac surgery.
    Authors: Tuinman P, Cornet A, Kuipers M, Vlaar A, Schultz M, Beishuizen A, Groeneveld A, Juffermans N
    BMC Pulm Med, 2013;13(0):76.
    Species: Human
    Sample Type: BALF
    Application: ELISA Development,
  2. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes.
    Authors: Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC
    Atherosclerosis, 2010;209(1):173-7.
    Species: Human
    Sample Type: Cell Lysates
    Application: Western Blot,
  3. Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium.
    Authors: Zen K, Chen CX, Chen YT, Wilton R, Liu Y
    J. Immunol., 2007;178(4):2483-90.
    Species: Human
    Sample Type: Whole Cells
    Application: Western Blot,
  4. Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells.
    Authors: Yamakawa N, Uchida T, Matthay MA, Makita K
    Am. J. Physiol. Lung Cell Mol. Physiol., 2011;300(4):L516-25.
    Species: Rat
    Sample Type: Cell Culture Supernates
    Application: ELISA Development,
  5. S100A11, an dual mediator for growth regulation of human keratinocytes.
    Authors: Sakaguchi M, Sonegawa H, Murata H, Kitazoe M, Futami J, Kataoka K, Yamada H, Huh NH
    Mol. Biol. Cell, 2007;19(1):78-85.
    Species: Human
    Sample Type: Cell Lysates
    Application: Western Blot,


No product specific FAQs exist for this product, however you may click here to view all FAQs for Primary Antibodies

Order Details

Contact Information

Certificate of Analysis Lookup

The document you requested is not available online. Please enter the Catalog Number and Lot Number below to have a document emailed to you at the address provided

Certificate of Analysis Lookup

Research Areas of Interest


Customer Information